Rating the quality of evidence for clinical practice guidelines

Journal of Clinical Epidemiology

Volumn 49, Issue 7, 1996, Pages 749-754

  Hadorn, David C ^a   Baker, David ^a   Hodges, James S ^b   Hicks, Nicholas ^c  

^a Health Science Program   (United States)

^b UNIVERSITY OF MINNESOTA   (United States)

^c Oxfordshire Dept of Public Health   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

BETA ADRENERGIC RECEPTOR BLOCKING AGENT; METOPROLOL;

CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CORONARY ARTERY RECANALIZATION; HEALTH CARE POLICY; HEALTH CARE QUALITY; HEART FAILURE; HUMAN; MEDICAL RESEARCH; PRACTICE GUIDELINE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SHORT SURVEY;

EID: 0030198414     PISSN: 08954356     EISSN: None     Source Type: Journal    
DOI: 10.1016/0895-4356(96)00019-4     Document Type: Article

References (41)

1. 1. Baker DW, Konstam MA, Bottorff M, Pitt B. Management of heart failure. 1. Pharmacologic treatment. JAMA 1994; 272: 1361-1366.
2. 2. Dracup K, Baker DW, Dunbar SB, Dacey RA, Brooks NH, Johnson JC, Oken C, Massie BM. Management of heart failure. II. Counseling, education, and lifestyle modifications. JAMA 1994; 272: 1442-1446.
3. 3. Baker DW, Jones R, Hodges J, Massie BM, Konstam MA, Rose EA. Management of heart failure. III. The role of revascularization in the treatment of patients with moderate or severe left ventricular systolic dysfunction. JAMA 1994; 272: 1528-1534.
4. 4. Baker DW, Wright RF. Management of heart failure. IV. Anticoagulation for patients with heart failure due to left ventricular systolic dysfunction. JAMA 1994; 272: 1614-1618.
5. 5. Hadorn DC, Baker D. Development of the Heart Failure Guideline: Methodological and procedural issues. Joint Commiss J Qual Improv 1994; 20: 539-546.
6. 6. Hadorn DC, Baker D, Dracup K, et al. Estimation of treatment effectiveness based on health outcomes: Theoretical and practical issues. Joint Commiss J Qual Improv 1994; 20: 547-554.
7. 7. Konstam M, Dracup K, Baker D, et al. Heart Failure: Evaluation and Care of Patients with Left-Ventricular Systolic Dysfunction. Clinical Practice Guideline No. 11. AHCPR Publication No. 94-0612. Agency for Health Care Policy and Research, Public Health Service, U.S. Department of Health and Human Services, Rockville, Maryland, 1994.
8. 8. U.S. Preventive Services Task Force. Guide to Clinical Preventive Services. William & Wilkins, Baltimore, Maryland, 1989, pp. xxxiii-xxxv.
9. 9. Canadian Task Force on the Periodic Health Examination. The periodic health examination. Can Med Assoc J 1979; 121: 1193-1254.
10. 10. Chalmers TC, Smith H Jr, Blackburn B, Silverman B, Schroeder B, Reitman D, Ambroz A. A method for assessing the quality of a randomized control trial. Controlled Clin Trials 1981; 2: 31-49.
11. 11. Liberati A, Himel HN, Chalmers TC. A quality assessment of randomized control trials of primary treatment of breast cancer. J Clin Oncol 1986; 4: 942-951.
12. 12. Gifford RH, Feinstein AR. A critique of methodology in studies of anticoagulant therapy for acute myocardial infarction. New Engl J Med 1969; 280: 351-357.
13. 13. Chalmers I. Evaluating the effects of care during pregnancy and childbirth. In: Effective Care in Pregnancy and Childbirth (Chalmers I, Enkin M, Keirse MJNC, eds.), Chap. 1. Oxford University Press, Oxford, 1989, pp. 3-38.
14. 14. Chalmers I, Enkin M, Keirse MJNC (eds.). Effective Care in Pregnancy and Childbirth. Oxford University Press, Oxford, 1989.
15. 15. Feinstein AR. Epidemiologic analyses of causation: The unlearned scientific lessons of randomized trials. J Clin Epidemiol 1989; 42: 481-489.
16. 16. Feinstein AR, Horwitz RI. Double standards, scientific methods, and epidemiologic research. New Engl J Med 1982; 307: 1611-1617.
17. 17. Feinstein AR. The role of observational studies in the evaluation of therapy. Stat Med 1984; 3: 341-345.
18. 18. Feinstein AR. Current problems and future challenges in randomized clinical trials. Circulation 1984; 70: 767-774.
19. 19. Feinstein AR. Experimental requirements and scientific principles in case-control studies. J Chron Dis 1985; 38: 127-133.
20. 20. Horwitz RI. The experimental paradigm and observational studies of cause-effect relationships in clinical medicine. J Chron Dis 1987; 40: 91-99.
21. 21. Clemens JD, Chuong JJH, Feinstein AR. The BCG controversy: A methodological and statistical reappraisal. JAMA 1983; 249: 2362-2369.
22. 22. Harvey M, Horwitz RI, Feinstein AR. Toxic shock and tampons: Evaluation of the epidemiologic evidence. JAMA 1982; 248: 840-846.
23. 23. McFarlane MJ, Feinstein AR, Horwitz RI. Diethylstilbestrol and clear cell vaginal carcinoma: Reappraisal of the epidemiologic evidence. Am J Med 1986; 81: 855-863.
24. 24. Buyse M, Zeleniuch-Jacquotte A, Chalmers TC. Adjuvant therapy of colorectal cancer: Why we still don't know. JAMA 1988; 259: 3571-3578.
25. 25. Jaeschke R, Oxman A, Guyatt G. To what extent do congestive heart failure patients in sinus rhythm benefit from digoxin therapy? A systemative overview and meta-analysis. Am J Med 1990; 88: 279-286.
26. 26. Alderman EL, Fischer P, Litwin GC, et al. Results of coronary artery surgery in patients with poor left ventricular function (CASS). Circulation 1983; 68: 785-795.
27. 27. Bounous E, Mark D, Pollock B, et al. Surgical survival benefits for coronary disease patients with left ventricular dysfunction. Circulation 1988; 78: 1151-1157.
28. 28. Faulkner SL, Stoney WS, Alford WC, et al. Ischemic cardiomyopathy medical versus surgical treatment. J Thorac Cardiovasc Surg 1977; 74: 77-78.
29. 29. Hammermeister KE, Rowen TA, Dodge HT. Comparison of survival of medically and surgically treated coronary disease patients in Seattle Heartwatch, a non-randomized study. Circulation 1982; 65: 53-59.
30. 30. Manley J, King J, Zeft H, et al. The "bad" left ventricle. Results of coronary surgery and effect on late survived. J Thorac Cardiovasc Surg 1976; 72: 841-848.
31. 31. Pigott J, Kouchoukos N, Oberman A, et al. Late results of surgical and medical therapy for patients with coronary artery disease and depressed left ventricular function. J Am Coll Cardiol 1985; 5: 1036-1045.
32. 32. Vliestra RE, Assad-Morell JL, Frye RL, et al. Survival predictors in coronary artery disease. Medical and surgical comparisons. Mayo Clin Proc 1977; 52: 85-90.
33. 33. Yatteau RF, Peter RH, Behar VS, et al. Ischemic cardiomyopathy: The myopathy of coronary artery disease. Am J Cardiol 1974; 34: 520.
34. 34. Anderson JL, Lutz JR, Gilbert EM, et al. A randomized trial of low-dose beta-blockade therapy for idiopathic dilated cardiomyopathy. Am J Cardiol 1985; 55: 471-475.
35. 35. Cucchini F, Compostella L, Papalia D, et al. Trattamento cronico della cardiomiopatia dilatativa con betabloccanti. Controllo clinico ed emodinamico a distanza. [Chronic treatment of dilated cardiomyopathy by beta blocking agents. Clinical and hemodynamic follow-up]. G Ital Cardiol 1988; 18: 835-842.
36. 36. Engelmeier RS, O'Connell JB, Walsh R, et al. Improvement in symptoms and exercise tolerance by metoprolol in patients with dilated cardiomyopathy: A double-blind, randomized, placebo-controlled trial. Circulation 1985; 72: 536-546.
37. 37. Yokota Y, Nomura H, Kawai H, et al. Effects of long-term beta-blockade (metoprolol) therapy in patients with dilated cardiomyopathy. Jpn Circ J 1991; 55: 343-355.
38. 38. Eddy DM, Hasselblad V, Shacter R. Meta-Analysis by the Confidence Profile Method. Academic Press, New York, 1992.
39. 39. Hospers NR. Observation. In: Introductory Readings in the Philosophy of Science (Klemke ED, Hollinger R, Koine AD, eds.). Prometheus Books, Buffalo, New York, 1980.
40. 40. Hanson NR. Observation and interpretation. In: Philosophy of Science Today (Morgenbesser S, ed.). Basic Books, New York, 1966.
41. 41. Holland J, Holyoak K, Nisbett R, Thagard P. Induction: Processes of Inference, Learning, and Discovery. MIT Press, Cambridge, Massachusetts, 1986.